Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in LLY — ELI LILLY & Co

CIK 1423053 MIAMI, FL
Back to LLY Full portfolio

Position in LLY

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$222,321,285
-$529,695,786 QoQ
Shares Held
241,714
-65.5% QoQ
Ownership
0.026%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in LLY Over Time

Shares Held

Position Value (USD)

Derivatives in LLY

reported options exposure · as of Mar 31, 2026
CallValue
$1,583,016,147
CallShares
1,721,100
PutValue
$1,454,892,186
PutShares
1,581,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $2,757,631,879 across 16 Drug Manufacturers - General names. LLY ranks #5 (8.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 GILD
Gilead Sciences, Inc.
 3,982,185 $554,997,122
2 JNJ
Johnson & Johnson
 1,930,976 $472,007,773
3 MRK
Merck & Co., Inc.
 3,821,227 $459,655,395
4 AZN
Astrazeneca PLC
 1,869,793 $368,760,574
5 LLY
ELI LILLY & Co
This page 		241,714 $222,321,285
6 PFE
Pfizer Inc
 7,359,865 $206,665,008
7 ABBV
AbbVie Inc.
 490,285 $106,632,084
8 NVO
Novo Nordisk A S
 2,736,525 $100,567,293

All Filings in LLY

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $222,321,285 241,714
2026-03-31 $1,583,016,147 1,721,100
2026-03-31 $1,454,892,186 1,581,800
2025-12-31 $2,403,414,575 2,236,400
2025-12-31 $2,244,791,792 2,088,800
2025-12-31 $752,017,071 699,759
2025-09-30 $1,775,653,600 2,327,200
2025-09-30 $879,600,134 1,152,818
2025-09-30 $1,701,032,200 2,229,400
2025-06-30 $2,915,052,435 3,739,500
2025-06-30 $1,341,181,365 1,720,500
2025-06-30 $665,135,530 853,252
2025-03-31 $1,598,713,987 1,935,700
2025-03-31 $1,362,338,545 1,649,500
2025-03-31 $394,604,105 477,781
2024-12-31 $1,433,372,400 1,856,700
2024-12-31 $1,658,101,600 2,147,800
2024-12-31 $471,904,300 611,275
2024-09-30 $190,638,340 215,182
2024-09-30 $1,277,259,698 1,441,700
2024-09-30 $1,615,600,184 1,823,600
2024-06-30 $1,182,516,818 1,306,100
2024-06-30 $1,079,394,036 1,192,200
2024-06-30 $453,445,992 500,835
2024-03-31 $1,114,194,312 1,432,200
2024-03-31 $1,344,859,452 1,728,700
2024-03-31 $371,174,828 477,113
2023-12-31 $743,824,573 1,276,032
2023-12-31 $929,582,524 1,594,700
2023-12-31 $765,373,960 1,313,000
2023-09-30 $408,107,613 759,793
2023-09-30 $730,174,522 1,359,400
2023-09-30 $615,712,119 1,146,300
2023-06-30 $593,634,884 1,265,800
2023-06-30 $256,120,295 546,122
2023-06-30 $616,474,210 1,314,500
2023-03-31 $343,385,658 999,900
2023-03-31 $85,862,211 250,021
2023-03-31 $259,934,598 756,900
2022-12-31 $64,649,049 176,714
2022-12-31 $393,241,416 1,074,900
2022-12-31 $501,822,728 1,371,700
2022-09-30 $802,490,030 2,481,800
2022-09-30 $475,324,500 1,470,000
2022-09-30 $317,945,204 983,285
2022-06-30 $377,755,509 1,165,085
2022-06-30 $166,751,489 514,300
2022-06-30 $276,470,921 852,700
2022-03-31 $11,948,501 41,724
2022-03-31 $222,996,319 778,700

Report a Problem

Category
Description
Email (optional, for follow-up)